drugset / Trial / NCT06280534
Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects
RandomizedSequentialDouble-blindTreatment
Summary
A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects.
Timeline
- Start
- 2023-07-18
- Primary completion
- 2024-02-29
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XT1061 | Unknown | 12.5 mg | — |
| Subject | XT1061 | Unknown | 25 mg | — |
| Subject | XT1061 | Unknown | 37.5 mg | — |
| Subject | XT1061 | Unknown | 62.5 mg | — |
| Subject | XT1061 | Unknown | 125 mg | — |
| Subject | XT1061 | Unknown | 250 mg | — |
| Subject | XT1061 | Unknown | 400 mg | — |
| Subject | XT1061 | Unknown | 800 mg | — |